Monday 17 Dec, 2018 10:11 PM
Site map | Locate Us | Login
   Kwality Ltd leads losers in 'A' group    Arihant Foundations & Housing Ltd leads losers in 'B' group    Kotak Mahindra Bank slips on buzz Bombay HC denies stay on RBI deadline    Volumes jump at D B Corp Ltd counter    Ahluwalia Contracts (India) spurts after winning order    Zee Media Corporation Ltd up for third consecutive session    Power Finance Corporation Ltd gains for third straight session    Bank of India increases for fifth straight session    Central Bank of India spurts 2.63%    Vedanta Ltd up for five straight sessions    Tech Mahindra Ltd gains for fifth straight session    NIIT Technologies Ltd soars 1.2%, rises for fifth straight session    GlaxoSmithkline Consumer Healthcare Ltd up for fifth straight session    Dabur India Ltd spurts 0.86%, gains for fifth straight session    Godrej Consumer Products Ltd soars 1.61%, rises for fifth straight session 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Aurobindo Pharma off day's low after USFDA nod
11-Oct-18   12:38 Hrs IST

The announcement was made during trading hours today, 11 October 2018.

Meanwhile, the S&P BSE Sensex was down 685.13 points, or 1.97% to 34,075.76

On the BSE, 86,000 shares were traded in the counter so far compared with average daily volumes of 1.89 lakh shares in the past two weeks. The stock had hit a high of Rs 776.50 and a low of Rs 752.90 so far during the day.

Aurobindo Pharma announced that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Azithromycin Oral Suspension 100 mg /5 mL and 200 mg/5 mL. Azithromycin oral suspension, a generic version of Pfizer Inc's Zithromax oral suspension. The product will be launched in November 2018.

Azithromycin oral suspension is indicated for the treatment of patients with mild to moderate infections. The approved product has an estimated market size of US$71 million for the twelve months ending August 2018, according to IQVIA.

This is the 125th ANDA (including 11 tentative approvals) to be approved out of Unit III formulation facility in Hyderabad used for manufacturing oral products. Aurobindo now has a total of 386 ANDA approvals (357 Final approvals including 19 from Aurolife Pharma LLC and 29 tentative approvals) from USFDA.

On a consolidated basis, Aurobindo Pharma's net profit fell 12.12% to Rs 455.66 crore on 15.48% increase in net sales to Rs 4181.56 crore in Q1 June 2018 over Q1 June 2017.

Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's product portfolio is spread over major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, Anti-Allergies and Anti-Diabetics.

Powered by Capital Market - Live News

   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.G Anand , anand@ssplwealth.com
Hit Count : 9952222
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016  |  MCX : INZ000081736
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 12815 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. Saravana Stocks Pvt. Ltd